Assignee
SCHOLAR ROCK INC
US·32 granted patents·32 pending applications·240 citations·filing 2013–2025
Top patents by PatentIndex Score
64 records- 0197US9580500B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Feb 28, 2017·36 cites·8 claims
- 0297US9573995B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Feb 21, 2017·41 cites·10 claims
- 0397US9399676B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Jul 26, 2016·38 cites·7 claims
- 0495US10597443B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Granted Mar 24, 2020·16 cites·23 claims
- 0594US12006359B2Methods for altering body composition by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2020·Granted Jun 11, 2024·3 cites·8 claims
- 0694US11827698B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2021·Granted Nov 28, 2023·2 cites·23 claims
- 0794US11439704B2Methods for using anti-myostatin antibodiesSCHOLAR ROCK INC·Filed 2020·Granted Sep 13, 2022·5 cites·12 claims
- 0894US10981981B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2018·Granted Apr 20, 2021·5 cites·24 claims
- 0994US10287345B2Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2017·Granted May 14, 2019·14 cites·11 claims
- 1094US9758576B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2015·Granted Sep 12, 2017·13 cites·10 claims
- 1194US9758577B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2016·Granted Sep 12, 2017·13 cites·16 claims
- 1292US11925683B2Compositions for making and using anti-Myostatin antibodiesSCHOLAR ROCK INC·Filed 2021·Granted Mar 12, 2024·2 cites·9 claims
- 1391US11135291B2Methods for making and using anti-myostatin antibodiesSCHOLAR ROCK INC·Filed 2019·Granted Oct 5, 2021·10 cites·26 claims
- 1491US10882904B2Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2019·Granted Jan 5, 2021·6 cites·19 claims
- 1591US10307480B2Anti-pro/latent-myostatin antibodies and uses thereofSCHOLAR ROCK INC·Filed 2015·Granted Jun 4, 2019·12 cites·19 claims
- 1690US12454570B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2023·Granted Oct 28, 2025·0 cites·19 claims
- 1790US10946036B2Use of myostatin inhibitors and combination therapiesSCHOLAR ROCK INC·Filed 2017·Granted Mar 16, 2021·6 cites·22 claims
- 1889US10751413B2Anti-pro/latent-Myostatin antibodies and uses thereofSCHOLAR ROCK INC·Filed 2016·Granted Aug 25, 2020·8 cites·11 claims
- 1988US11214614B2LTBP complex-specific inhibitors of TGFβ and uses thereofSCHOLAR ROCK INC·Filed 2020·Granted Jan 4, 2022·2 cites·3 claims
- 2088US11155611B2Compositions and methods for making and using anti-myostatin antibodiesSCHOLAR ROCK INC·Filed 2018·Granted Oct 26, 2021·5 cites·7 claims
- 2186US11365245B2LTBP complex-specific inhibitors of TGFβ and uses thereofSCHOLAR ROCK INC·Filed 2021·Granted Jun 21, 2022·1 cites·8 claims
- 2285US12122823B2Isoform-selective TGFB1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2021·Granted Oct 22, 2024·1 cites·13 claims
- 2383US2024391989A1Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 2482US2025179164A1LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 2579US2024374718A1Anti-pro/latent-myostatin antibodies and uses thereofSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 2678US2024016928A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 2777US12582712B2Method of making anti-pro/latent myostatin antibodiesSCHOLAR ROCK INC·Filed 2022·Granted Mar 24, 2026·0 cites·8 claims
- 2877US11130803B2Isoform-selective TGFβ1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Granted Sep 28, 2021·1 cites·10 claims
- 2977US2025215072A1Isoform-selective tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 3075US12173059B2LTBP complex-specific inhibitors of TGFβ and uses thereofSCHOLAR ROCK INC·Filed 2022·Granted Dec 24, 2024·0 cites·20 claims
- 3173US12577296B2Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2020·Granted Mar 17, 2026·0 cites·11 claims
- 3269US2023348583A1TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFSCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 3368US12338279B2Selective and potent inhibitory antibodies of myostatin activationSCHOLAR ROCK INC·Filed 2024·Granted Jun 24, 2025·0 cites·11 claims
- 3467US12281159B2TGFβ antibodies, methods and usesSCHOLAR ROCK INC·Filed 2021·Granted Apr 22, 2025·0 cites·26 claims
- 3567US2018022798A1Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Application pending·0 cites
- 3667US2026035447A1Methods for treating metabolic diseases by inhibiting myostatin activationSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 3766US2018016332A1Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Application pending·0 cites
- 3864US2017210798A1Compositions and methods for growth factor modulationSCHOLAR ROCK INC·Filed 2017·Application pending·0 cites
- 3964US2022106390A1Methods for treating metabolic diseases by inhibiting myostatin activationSCHOLAR ROCK INC·Filed 2021·Application pending·0 cites
- 4064US2019209682A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Application pending·0 cites
- 4163US12252531B2Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitorsSCHOLAR ROCK INC·Filed 2019·Granted Mar 18, 2025·0 cites·5 claims
- 4260US2018207267A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2018·Application pending·0 cites
- 4360US2025304669A1Rgmc-selective inhibitors and use thereofSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 4459US2021283166A1Use of myostatin inhibitors and combination therapiesSCHOLAR ROCK INC·Filed 2021·Application pending·0 cites
- 4558US2024301073A1LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOFSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
- 4658US2025257125A1HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOFSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 4757US2026035448A1Selective and potent inhibitory antibodies of myostatin activationSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 4857US2025326827A1Use of myostatin inhibitor for treating spinal muscular atrophySCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 4956US12297262B2RGMC-selective inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Granted May 13, 2025·0 cites·35 claims
- 5056US2024294623A1Tgf-beta inhibitors and therapeutic use thereofSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SCHOLAR ROCK INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →